Shen Huifen, Zuo Fei
Department of Neurology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China.
Department of Gastroenterology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China.
Front Oncol. 2024 Dec 11;14:1465279. doi: 10.3389/fonc.2024.1465279. eCollection 2024.
The significance of the systemic inflammation response index (SIRI) in predicting the prognosis of patients with pancreatic cancer (PC) has been extensively explored; however, findings remain controversial. As such, this meta-analysis was performed to more precisely determine the utility of the SIRI in predicting PC prognosis.
A comprehensive literature search of the PubMed, Web of Science, Embase, and Cochrane Library databases for relevant studies, published up to June 25, 2024, was performed. The primary and secondary endpoints were overall survival (OS) and progression-free survival (PFS), respectively. The prognostic utility of the SIRI in predicting PC prognosis was estimated by calculating pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs).
Seven studies comprising 1160 patients were included in the present meta-analysis. Pooled findings revealed that elevated SIRI was as a prominent prognostic marker of OS (HR 2.40 [95% CI 1.88-3.05]; p<0.001) and PFS (HR 1.95 [95% CI 1.19-3.21]; p=0.008) in patients diagnosed with PC. According to subgroup analysis, the SIRI remained an outstanding prognostic marker for OS, irrespective of region, sample size, study center, study design, TNM stage, cancer type, cut-off value, treatment, or survival analysis type (all p<0.05). Moreover, based on subgroup analysis, the SIRI demonstrated significant utility in predicting PFS, irrespective of region and threshold value (p<0.05).
Results of the present meta-analysis revealed that an increased SIRI significantly predicted OS and PFS in patients diagnosed with PC. Considering its cost-effectiveness and availability, the SIRI may be a promising biomarker for predicting prognosis in patients with PC.
系统性炎症反应指数（SIRI）在预测胰腺癌（PC）患者预后中的意义已得到广泛探讨；然而，研究结果仍存在争议。因此，进行了这项荟萃分析，以更准确地确定SIRI在预测PC预后中的效用。
对截至2024年6月25日发表的相关研究进行了全面的文献检索，检索数据库包括PubMed、Web of Science、Embase和Cochrane图书馆数据库。主要和次要终点分别为总生存期（OS）和无进展生存期（PFS）。通过计算合并风险比（HRs）和相应的95%置信区间（CIs）来评估SIRI在预测PC预后中的预后效用。
本荟萃分析纳入了7项研究，共1160例患者。汇总结果显示，SIRI升高是诊断为PC的患者OS（HR 2.40 [95%CI 1.88 - 3.05]；p<0.001）和PFS（HR 1.95 [95%CI 1.19 - 3.21]；p = 0.008）的显著预后标志物。根据亚组分析，无论地区、样本量、研究中心、研究设计、TNM分期、癌症类型、临界值、治疗或生存分析类型如何，SIRI仍然是OS的优秀预后标志物（所有p<0.05）。此外，基于亚组分析，无论地区和临界值如何，SIRI在预测PFS方面都具有显著效用（p<0.05）。
本荟萃分析结果显示，SIRI升高显著预测了诊断为PC的患者的OS和PFS。考虑到其成本效益和可获得性，SIRI可能是预测PC患者预后的有前景的生物标志物。
